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Therefore, EGFR signalling in colon cancer is modulated at the
level of receptor capacity, receptor heterodimerization, regulation
of intracellular tyrosine kinase activity, ligand presentation and
by other costimulatory receptor pathways. These mechanisms
have to be considered when therapeutic strategies using EGFR-
inhibition are evaluated.
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Colorectal cancer is one of the most prevalent cancers world-
wide. Whereas surgery is the basis of therapy, chemo- and/or
radiotherapy are used frequently to reduce local and distant
recurrences. Many prognostic factors have been defined, with
only the UICC classification being relevant for therapeutic deci-
sions at present. The prognosis for an individual patient, how-
ever, still cannot be sufficiently predicted. Therefore, many
patients will receive radio-/chemotherapy that do not benefit
from this treatment. Other patients might not receive radio-/che-
motherapy as they are judged to be at a low risk for recurrence,
but will develop recurrent disease. Better prognostic factors are
therefore needed, in order to individualize the therapeutic strat-
egy. As recurrences after complete tumor removal are most likely
caused by disseminated tumor cells, it seems to be a logical
approach to develop methods to detect these cells. Ideally,
patients in whom tumor cells can be detected should have a
worse prognosis and should therefore benefit from adjuvant
therapeutic strategies. The effect of this therapy should then
become apparent by a reduced detection rate of disseminated
tumor cells. Even though some studies demonstrate a prognostic
relevance of disseminated tumor cells, the prognostic relevance
of these cells is not generally accepted. Due to the heterogeneity
of disseminated tumor cells, demonstration of the mere pres-
ence of these cells will most likely not be an adequate basis
for therapeutic decisions. Molecular characterization of dissemi-
nated tumor cells and/or of the primary tumor might be a more
successful approach in this respect. The clinical relevance of
molecular staging for therapeutic decisions, however, has still
to be proven in well designed clinical trials.
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Bisphosphonates have been used extensively for more than 3 dec-
ades to inhibit osteoclastic activity in a variety of benign and
malignant diseases characterized by increased bone resorption.
Due to the bisphosphonate moiety, these compounds bind avidly
to bone mineral and accumulate at sites of active bone turnover.
During bone resorption they are released and ingested by osteo-
clasts via fluid-phase endocytosis. The nitrogen-containing bis-
phosphonates (N-BPs) inhibit a key intracellular enzyme in the
mevalonate pathway, farnesyl pyrophosphate synthase, thereby
reducing prenylation of small GTPase signalling proteins that
are essential for osteoclast function and survival. Consequently,
bone resorption is impaired and osteoclast apoptosis is induced.
Zoledronic acid (Zometa) is a novel compound which retains
the bisphosphonate ‘‘bone hook’’ and possesses a heterocyclic
imidazole substituent containing 2 nitrogen atoms. X-ray crystal-
lography studies with human farnesyl pyrophosphate synthase
have shown that the zoledronic acid molecule binds with high
affinity to the active site of the enzyme and induces an irrevers-
ible conformational change that prevents further access of sub-
strate. Structure-activity studies with more than 300 novel
compounds identified zoledronic acid as the lead candidate for
clinical development due to its outstanding potency as an inhib-
itor of osteoclastic bone resorption both in vitro and in vivo, and
its excellent in vivo tolerability.
In animal models of breast cancer, prostate cancer, osteosar-
coma and haematological malignancies such as multiple mye-
loma and leukaemia, low doses of zoledronic acid markedly
inhibit osteoclastic activity and thus reduce tumour-induced oste-
olysis and hypercalcaemia. Bone is a rich source of growth factors
which are released during bone resorption and can stimulate
tumour cell proliferation. By inhibiting osteoclastic activity, zoled-
ronic acid reduces the release of tumour growth factors from bone
and thus interrupts this stimulatory cycle. Furthermore, the high
local concentration of bisphosphonate at an osteolytic site may
exert direct cytostatic and apoptotic effects on the tumour cells
in a bone metastasis. Extensive in vitro data show that zoledronic
acid is cytostatic and pro-apoptotic against a variety of human
tumour cell lines. Interestingly, zoledronic acid enhances the effi-
cacy of some cytotoxic drugs in a synergistic manner, especially
when the drugs are administered sequentially rather than con-
comitantly. Apart from these direct effects on tumour cell prolifer-
ation and viability, N-BPs also impair the metastatic behaviour of
tumour cells and modulate the host’s response to neoplastic dis-
ease. In vitro, zoledronic acid potently inhibits tumour cell inva-
sion through extracellular matrix, decreases cell adhesion to
both mineralized and non-mineralized matrices, and disrupts soft
tissue angiogenesis. Preclinical data from a variety of animal
tumour models demonstrate that, in vivo, these effects translate
into reduced tumour load, increased tumour cell apoptosis, and
in some cases delayed disease progression with a corresponding
survival benefit. Although these effects have been predominantly
observed in models of bone metastases in nude mice, emerging
data indicate that zoledronic acid can also inhibit the growth of
primary soft tissue tumours in transgenic animals by a mecha-
nism that apparently involves inhibition of angiogenesis and dis-
rupted macrophage function.
Recently, another intriguing facet has been added to the phar-
macological profile of the N-BPs. It has been known for many
years that these compounds interact with the immune system
to produce an acute phase response in a significant proportion
of patients, especially when administered intravenously, but the
molecular mechanism remained elusive. It is now known that
this effect is caused by inhibition of farnesyl pyrophosphate syn-
thase in monocytes, leading to accumulation of upstream metab-
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